High Dose Atorvastatin for Preventing Contrast-induced Nephropathy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Contrast-Induced Nephropathy
Interventions
DRUG

Atorvastatin

DRUG

Placebo

DRUG

0.9% sodium chloride

Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.

Trial Locations (1)

Unknown

Alzahra Hospital, Isfahan

All Listed Sponsors
lead

Isfahan University of Medical Sciences

OTHER

NCT02114346 - High Dose Atorvastatin for Preventing Contrast-induced Nephropathy | Biotech Hunter | Biotech Hunter